Healthcare

Abbott Laboratories (ABT) is due to report first-quarter 2026 results before the market opens on April 16, 2026, according to…

Abbott Laboratories (NYSE: ABT) enters fiscal 2026 with a growing profile, increasingly driven by sustained momentum in medical devices—particularly diabetes…

Johnson & Johnson (NYSE: JNJ) ended fiscal 2025 on a high note, reporting higher revenues and strong earnings growth for…

Zenas BioPharma, Inc. (ZBIO) reported Q4 2025 GAAP loss of $1.39 per share, a wider loss than the -$1.19 estimate…

Alto Neuroscience reports Q4 loss of $2.19/share, 434% wider than the $0.41 estimate, with zero revenue as clinical-stage biotech continues…

HealthEquity reports Q4 fiscal 2026 on March 17 with Wall Street expecting 30% EPS growth, but recent price target cuts…

**Minerva Neurosciences Reports Q4 2025 Results**

**Verrica Pharmaceuticals Reports Q4 2025 Results**

Rapport Therapeutics Inc (RAPP) posted a Q4 2025 gaap loss of $0.72 per share, wider than the -$0.67 expected loss…

**Nuwellis Inc Reports Q4 2025 Results**